NLRP3 and early-onset autosomal dominant Alzheimer disease: The activation of NLRP3 inflammasome correlates with a variety of diseases, including peritonitis (Qin and Zhao, 2023), arthritis (Wang et al., 2023), Alzheimer’s disease (AD) (Lv et al., 2023), and ischemic stroke (Han and Le, 2023), etc. Hence, the therapeutic efficacy of NLRP3 inflammasome inhibitors, which have manifested significant prognostic improvements in animal models of these diseases, underscores the imperative for their discovery.